Which reversal drug causes fewer bathroom problems after surgery?

NCT ID NCT06948409

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed records of 70,000 adults who had non-urinary surgery under general anesthesia. It compared two drugs used to reverse muscle relaxants: sugammadex and neostigmine (given with atropine or glycopyrrolate). The goal was to see which drug is linked to fewer cases of postoperative urinary retention, which can delay discharge from the recovery room. The study also looked at costs and unplanned hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sugammadex or neostigmine (with atropine or glycopyrrolate)
What this could lead to
If this study finds one reversal drug causes less urinary retention, it could help doctors choose the safer option for patients after surgery.
What could go wrong
This is a retrospective study, meaning it looks back at past records, so it cannot prove cause and effect. Other factors could influence the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Surgical patients at Beth Israel Deaconess Medical Center between September 2016 and January 2024

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients * Non-urinary system surgery * General anesthesia * Use of rocuronium or vecuronium for neuromuscular blockade * Neuromuscular blockade reversal with sugammadex or neostigmine (with atropine and/or glycopyrrolate) * Postoperative admission to the post-anesthesia care unit (PACU) Exclusion Criteria: * American Society of Anesthesiologists (ASA) physical status ≥ V * Emergency reversal with sugammadex (≥ 16 mg/kg of sugammadex) * Presence of foley or suprapubic catheter before or after the procedure * Prior history of bladder resection surgery * Observations with missing data for pre-specified confounding variables

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COFS syndrome Urinary Retention

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.